Editorial Board Disclosure Policy

(Last updated April 2022)
All editors responsible for recommending or making publication decisions are requested to disclose on an annual basis any potential conflict of interest, including current or recent financial relationships with any commercial entity whose products or services may be contained in the journal content.
The following competing interests were disclosed:
Saba Balasubramanian – Dr Balasubramanian received an honorarium for a lecture from Sandoz-Novartis.
Romana Netea-Maier – Professor Netea-Maier has represented her institution as part of advisory boards and has given presentations or attended conferences sponsored by EISAI and Lilly. Her insitiution has received remuneration for her services within the lawfully permitted limits. She has received through her institution independent grants for investigator-initiated studies as well as travel expenses from EISAI.
Simon H Pearce – Professor Pearce has received consulting fees for BioPharma companies including Worg and OSE.
Luca Persani – Professor Persani has received consulting fees from Merck, Sandoz, Ipsen and Pfizer.
Patrice Rodien – Dr Rodien has received payment for expertise from Pfizer, EISAI, Ipsen, NOVO Nordisk, HRA Pharma and Sandoz. He also received hospitality from Sandoz for the French endocrine society congress 2021.
The following editors reported no competing interests:
  • Jens Mittag
  • Furio Pacini
Bioscientifica staff and freelancers working on the journal reported no conflicts of interest. Article authors' declarations are stated in each journal article. Referees must disclose any competing interests before agreeing to review any submission. For more information on the journal’s ethical policy, please read the ethical guidelines.
This policy follows the recommendations of the International Committee of Medical Journals Editors (ICMJE) and the Committee on Publication Ethics (COPE).